Skip to main content
PLOS One logoLink to PLOS One
. 2019 Nov 5;14(11):e0224659. doi: 10.1371/journal.pone.0224659

Health impact of hepatic-venous-occlusive disease in a small town in Ethiopia—Case study from Tahtay koraro district in Tigray region, 2017

Kissanet Tesfay Weldearegay 1,*,#, Mekonnen Gebremichael Gebrekidan 2,#, Alefech Adissu Gezahegne 1,#
Editor: Raffaele Serra3
PMCID: PMC6831030  PMID: 31689340

Abstract

Background

Hepatic venous-occlusive disease is blockage of microscopic veins in the liver causing 20–50% mortality. Ingestion of pyrrolizidine alkaloid plant, radiation therapy, and post-bone-marrow-transplant reactions are the commonest causes. In Ethiopia, a venous-occlusive disease outbreak was identified in 2002 in Tahtay Koraro district, Tigray. Suspected due to ingestion of the toxic pyrrolizidine alkaloid plant Ageratum conyzoids, found throughout the district. We aimed to describe the surveillance data of venous-occlusive disease from September 2006 to August 2016 in Tahtay koraro district, Ethiopia, 2017.

Methodology

We defined a possible Hepatic venous-occlusive disease case as any patient with abdominal pain for at least 2 weeks, abdominal distention, and hepato-splenomegaly during September 2006-August 2016. We reviewed previous district line lists, weekly reports, and clinical records to identify and describe cases. Agricultural interventions were obtained from the agricultural offices of the district.

Result

We identified 179 possible cases with 83 deaths with a case-fatality rate of 46.3%. Among cases, 110 (61.5%) were males and 113 (63%) were >15 years. In total, 164 (91.6%) cases were from one village (Kelakil). The pick number of cases of VOD in this village was during 2008/09 which was 1076. The highest incidence (86/100,000) occurred in 2008. During the study period, 2,746 years of potential life were lost due to Hepatic venous-occlusive disease. Mechanical removal of the Ageratum started in 2011.

Conclusion

Hepatic venous-occlusive disease was an ongoing problem in Tahtay Koraro; However, the problem has largely been alleviated by displacing people from the affected area and removing the causative weed. More research is needed to understand why Kelakil village was more affected despite the widespread presence of the weed. Chemical and mechanical removal of the Ageratum could strengthen intervention activities.

Introduction

The venous-occlusive disease of the liver (VOD) is blockage of the very small veins in the liver. Because flow out of the liver is blocked, blood backs up in the liver. VOD is thought to be caused by damage to sinusoidal endothelial cells and hepatocytes in zone three of the liver [15].

Common causes include; Ingestion of pyrrolizidine alkaloids (PAs), use of certain drugs that occasionally have toxic effects on the liver including cyclophosphamides and azathioprine, radiation therapy, a reaction after bone marrow or stem cell transplantation, contraceptive and, several antineoplastic drugs [4, 6, 7].

Around 3% of the world’s flowering plants have one or more of the toxic PAs. The cause of VOD can be carelessly harvested wild weed with grain crops and consumption of flour contaminated by these plants [6]. Consumption of PAs-containing food or plants not necessarily causes signs of VOD. Because it depends on the dose consumed [8].

Sign of symptoms of VOD is characterized by the triad of weight gain caused by fluid retention, tender hepatomegaly and hyperbilirubinemia [4, 7, 9]. Diagnosis is conducted usually based on signs and symptoms, having ruled out other conditions that can mimic the disease [9]. Confirmation diagnosis is often conducted using Doppler ultrasonography [4]. Histological biopsy of the liver is the gold standard for the diagnosis of VOD [8].

Two-thirds of patients who died have multi-organ failure, this causes difficulty in knowing the main cause of death. In different kinds of literature, it has been reported that the incidence of VOD varies from 0 to 70% and its mortality from 20 to 50% [6].

In Western Afghanistan, Gulran District from 1974 to 1976 the largest outbreak of VOD was recorded causing an estimated 7800 people with about 1600 deaths with a case fatality rate of 20.5%[10].

In November-December 1975, in Sarguja district of India; the VOD outbreak was reported due to consumption of cereals mixed with seeds of the plant (Crotalaria sp.) containing pyrrolizidine alkaloids [11].

In northern Iraq in 1998, an outbreak of VOD resulted in 14 patient admissions to Mosul hospital the entire patient had VOD of the liver as confirmed by histopathological examination. The underlying causative agent was isolated from the contaminated wheat and flour and found to be pyrrolizidine alkaloids [1].

In Ethiopia, a liver disease of unknown etiology, called the unknown liver disease by the community, was first identified in 2002 in kelakil kebelle, Tahtay koraro district, northwestern Tigray; a rugged, semi-arid, mountainous region [12]. From that area sacrificed animal liver on histopathological examination test result showed severe hepatic necrosis. The serum sample test result indicated raised level of some clinical markers that are highly significant for detecting liver abnormality of toxic origin [13]. On analysis of risk factors for the cause showed that unprotected drinking water source was associated with the VOD [14, 15]. The aim of this study is to assess the surveillance data of VOD from September 2006 to August 2016 in Tahtay koraro district, North West Zone of Tigray region, Ethiopia, 2017.

Methods

Study area and period

Tahtay koraro district is found at altitude & latitude 140 06’ 00”north 380 16’ 00”meters above & below the sea level. The climatic condition of the district is 2% high land, 75% semi-lowland and, 23% lowland. The annual temperature is estimated to be between 15°c to 25°c. The annual rainfall range is 726–1400 mm. In 2017, the district’s total population was 78,311 [16]. The study was conducted from February to March 2017 in Tahtay Koraro district, Tigray Region of Ethiopia.

VOD standard case definitions

Suspected VOD case: is defined as a person with abdominal distention and either a household member sick with similar symptoms or abdominal cramp/pain for at least two weeks [17].

Possible VOD case: is defined as a person who meets the suspected case definition and has hepatomegaly or splenomegaly [17].

Probable VOD case: is defined as a person who meets the possible case definition and has a serum alkaline phosphatase greater than or equal to twice the upper limit of the normal [17].

Study design

A cross-sectional study was conducted.

Source population

Populations of Tahtay koraro district from 2006 to 2016.

Study subjects

All Possible and Suspected VOD cases and deaths registered on line list of Tahtay koraro district from September 2006 to August 2016.

Study units

A person who has the disease in the analysis period.

Data collection and analysis

Using structured checklist VOD cases of the last ten consecutive years were reviewed and collected from the line lists and weekly reports of the district health office. Data was reviewed, cleaned, entered and analyzed using Microsoft Excel.

Ethics approval and consent to participate

Ethical clearance was obtained from an ethical review board of Mekelle University, College of Health Sciences and Department of Public Health. A letter of permission was written from the Tigray Regional Health Bureau to Tahtay Koraro district health office. The study was done after permission was obtained from Tahtay Koraro district health office. Informed consent was waived by ethical review board. The confidentiality of information regarding patients involved in this study was maintained by avoiding identifying study participants by name.

Results

In Tahtay koraro district a total of 179 Hepatic VOD cases and 83 deaths were reported during the study time. The case fatality rate (CFR) was 46.3%. Males accounted for 110(61.5%) of the VOD cases.

All the cases were diagnosed without laboratory confirmations. Of the total cases, 88(49.72%) were possible cases and 54(30.17%) were suspected cases, and 37(20.7%) were not properly registered.

The median age of cases was 29, ranges from 1 to 78 Years. When we see the age distribution, <5 years of age 14(8%), 5–14 years of age 52(29%) and above 15 years of age group accounted 113(63%) (Fig 1).

Fig 1. HVOD case by age categories in Tahtay koraro district from September 2006 to August 2016.

Fig 1

Among the total 83 deaths, 57(69%) were males. The median ages of the VOD deaths were 30.5. Of the total deaths above 15 years of age accounted for 58(70%), 5–14 years of ages were 23(28%), and less than 5 years were 2(1.1%). During the ten years, 2746 years of potential life lost (YPLL) were attributed due to VOD. During the ten years period, there was no female death among less than five years of children’s. While 17(65.4%) females and 41(72%) males’ deaths occurred among the age group of above 15 years (Fig 2).

Fig 2. The proportion of HVOD deaths by sex and age, in Tahtay koraro during 2006–2016.

Fig 2

During the ten years period of analysis, Of all cases, 164 (91.6%) were occurred in Kelekil kebelle, while the other kebelles of Tahtay koraro contributed less than eight percent of the total cases. From the total cases in Kelakil kebelle, 172(96%) cases have occurred in Tsaeda emba sub kebelle.

In the district, the highest incidence rates of VOD cases were 86 per 100,000 populations from September 2008 to August 2009. While the lowest incidence rates were 3 cases per 100,000 populations from September 2015 to August 2016.

The highest affected Kebelle of the district was Kelakil with the highest incidence rate of 1076 cases from September 2008 to August 2009 and the lowest 33 cases from September 2015 to August 2016 per 100,000 populations. It was the only kebelle which had the disease throughout the ten years of analyzed data. (Table 1).

Table 1. Ten year’s incidence rates of HVOD case in Tahtay koraro district, during 2006–2016.

Sr.no years The incidence rate in sub kebelles per 100,000 population Incidence of the district per 100,000 population
Kelakil Beles Tahtay adigebru Lemlem adigidad adimenabir mydemu
1 2006/07 919 0 0 0 0 0 0 74
2 2007/08 936 0 0 0 0 0 0 75
3 2008/09 1076 0 0 0 0 0 0 86
4 2009/10 242 33 123 48 0 0 0 19
5 2010/11 195 0 60 0 41 119 0 15
6 2011/12 94 0 0 0 0 0 0 8
7 2012/13 55 0 0 0 0 0 0 4
8 2013/14 105 0 0 0 0 0 0 8
9 2014/15 51 0 0 0 0 0 0 4
10 2015/16 33 0 0 0 0 0 14 3

NB. The first year started in September and ends in August of the consecutive year.

The incidence rate of the cases started to decrease dramatically from 86 cases in 2008/09 to 19 cases in 2009/10 in the district and from 1076 cases in 2008/09 to 242 cases in 2009/10 in Kelakil kebelle per 100,000 populations, since then the disease was started to decrease and in 20015/16 the incidence rate was only 3 and 33 cases per 100,000 populations in the district and in Kelakil kebelle respectively. As the incidence rate in the kebelle decreases, the incidence rate in the district also decreases (Fig 3).

Fig 3. Ten-year incidence rate of Tahtay koraro district and kelakil kebelle, Tigray, from 2006 to 2016.

Fig 3

The prevalence of VOD in the district in 2015/16 was 3 cases per 1000 populations while in Kelakil kebelle 34 cases per 1000 populations.

Out of the 83 deaths, 79(95%) deaths occurred in Kelakil kebelles while Tahtay adigebaro accounted for two deaths and Beles and lemlem kebelles accounted for one case each. The case fatality rate of VOD among males was 52%(57/110) while among females was 38%(26/69). In Kelakil kebelle the case fatality rate was 48% (79 out of 164). In the district, the case fatality rate of VOD was started to decrease gradually, from 17 (40.5%) in 2006/07 to 2 (1.9%) in 2015/16 (Fig 4).

Fig 4. Trends of HVOD by case fatality rate, in Tahtay koraro district, from 2006 to 2016.

Fig 4

Discussion

In 2008 in the district, the highly affected Tsaedaemba sub kebelle residents were displaced to the lowly affected Endabanou sub kebelle within the Kelakil kebelle for decreasing the incidence and mortality of the disease.

Even though the district had not organized data regarding intervention activities of unweeding of the ageratums since 2011 Kelakil kebelle residents started unweeding of the ageratum. In 2016 un weeding of the ageratum have been started in all kebelles of the district, and Out of 9092 hectares to being unwedded, mechanically unweeding of the ageratum was done in July and September, with 8099(89%) and 8829(97%) of hectares respectively [16].

Our study finding conducted from September 2006 to August 2016 in Tahtay koraro district showed that, out of a total of 179 VOD cases, 110 (61.5%) were males. Similarly the analysis (from 2002 to 2012) of a study conducted in northwestern Tigray of Ethiopia showed that; out of total 1095 VOD cases, 766(70%) were males. And another outbreak study of VOD happened in 1998 in northern Iraq showed that; out of the 14 patient 8(57%) of them were males [6, 17]. The studies have indicated that males were highly affected. The reason might be due to alcohol consumption is higher in males than females and alcohol has the ability to enhance the enzyme Cytochrome P450 which is responsible for the conversion of nontoxic PAs to toxic metabolites in the liver.

The median age of the cases was 29 years, which was similar to the study conducted in northwestern Tigray which was 30 years [17]. In our study, the minimum and maximum age ranges of cases were 1 to 78 years. This was almost the same as the study conducted in northern Tigray, which ranges 1 to 81 years. The reason for one year’s old child case might be due to PAs has been found in human milk during PA poisoning epidemics. So that children’s might have the disease during breastfeeding. From this finding, we understand that VOD can affect all age categories. Our study showed that; the age groups above 15 years were more affected 52(29%). This is similar compared with a study conducted in northwestern Tigray indicated that age group above 15 years was the dominant affected group [17]. The reason might be, adults are more participated in drinking alcohol and eating raw meats like animal liver, so that they were more at risk getting off the disease.

Majority of the cases 164 (91.6%) were in Kelakil kebelle of the district. This might be due to the reason that the residents were consuming more PAs than others kebelles. Also, it could be due to the reason that the area might have high acid in the soil which decreases the organic matters of the soil and enhancing the growth of the ageratum weeds. If the density of ageratum weed is high, obviously VOD cases will be increased. And also the kebelle might be less involved in an unweeding of the ageratum before and after harvest than the other kebelles.

In this study, the incidence rate started to decrease dramatically from 86 cases in 2008/09 to 19 cases in 2009/10. In Kelakil kebelle of the district, there was decrement of cases per 100,000 populations from 1076 in 2008/09 to 242 in 2009/10. This decrement might be due to the displacement of residents from Tsaedaemba sub kebelle which were highly affected area to lowly affected area Endabanou sub kebelle within kelakil kebelles in 2008. Since then the disease was decreasing gradually and in 20015/16 the incidence rate was 3 and 33 cases per 100,000 populations in the district and in Kelakil kebelle respectively. In addition to the above reason, the decrement might be due to the intervention activities done in 2011. Activities such as unweeding of ageratum weed and health education activities given to the residents on the importance of weeding crops by health extension workers. And also there might be under-reporting of cases especially after the finding of the causative agent.

During the analysis period of our study, the district’s case fatality rate of hepatic VOD was 46.4% (83 out of 179 cases). Which is more than two times higher than an outbreak happen in a study done in, Western Afghanistan Gulran District 1974–1976, with a case fatality rate of 20.5%(1600 out of 7800). And also it was higher compared with analysis conducted in northwestern Tigray region from 2002–2012, which was 27.6% (302/1095), whereas it is almost similar to findings from India, Sarguja district, 1975 with case fatality rate of 42% (28 out of 67 cases) [10, 17].

In this study, the case fatality rate of VOD among males was 51.8%(57/110) and in females 37.7%(26/69). This result disagrees with the result of northwestern zone of Tigray 25.6% (196/766) among males and 32.2% (106/329) in females.

Our study reveled that, the case fatality rate of VOD was started to decrease gradually from 17(40.5%) in 2006/07 to 2 (1.9%) in 2015/16. The reason might be due to the improvement of the health professional’s capacity for clinical care and management.

Conclusion

A VOD case with a high case fatality rate was identified in Tahtay Koraro District, northwestern Tigray of northern Ethiopia during the ten years of analysis. Cases and case fatality rates were higher among males. The above 15 years of age group were the dominant group affected. The majority of the cases were from Kelakil Kebelle of the district. In the district, the highest incidence rate of VOD cases was occurred in 2008/09, while the lowest was in 2015/16. After the displacement of the highly affected villages, intervention activities of unweeding of the ageratum weed, and proper case management started and cases fatality rate of VOD decreased significantly. More research is needed to understand why Kelakil village was more affected despite the widespread presence of the weed. Chemical and mechanical removal of the Ageratum could strengthen intervention activities.

Limitation

There was no complete registered data of some variables. Even though there were 83 deaths, it was difficult being sure that the causes of the deaths were only VOD, there might be coincidental events or other factors during the time because the death of the report was community-based.

Supporting information

S1 File. Data available.

(SAV)

Acknowledgments

We would like to thank Mekelle University, College of Health Science, Department of Epidemiology, and Tahtay Koraro district health office staff. Finally, we would like to thank all our family and friends for their essential support.

Abbreviations

CFR

Case Fatality Rate

PA

Pyrrolizidine Alkaloid

VOD

Venous-Occlusive Disease

YPLL

Years of Potential Life Lost

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Richardson P, Guinan E. The pathology, diagnosis, and treatment of hepatic veno‐occlusive disease: current status and novel approaches. British journal of haematology. 1999;107(3):485–93. 10.1046/j.1365-2141.1999.01680.x [DOI] [PubMed] [Google Scholar]
  • 2.Bearman S. Avoiding hepatic veno-occlusive disease: what do we know and where are we going? Bone marrow transplantation. 2001;27(11):1113 [DOI] [PubMed] [Google Scholar]
  • 3.Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Reviews. 2003;17(2):63–70. [DOI] [PubMed] [Google Scholar]
  • 4.T.Orfanidis N. Veno-occulusive disease of the liver 2016.
  • 5.Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85(11):3005–20. [PubMed] [Google Scholar]
  • 6.Altaee MY. An outbreak of veno-occlusive disease of the liver in northern Iraq. 1998.
  • 7.Carreras EGA, Rozman C. hepatic veno-occulusive disease after bone marrow transplant. Blood Reviews. 1993;7:43–51. [DOI] [PubMed] [Google Scholar]
  • 8.Chen Z, Huo J-R. Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations. Neth J Med. 2010;68(6):252–60. [PubMed] [Google Scholar]
  • 9.Senzolo M, Germani G, Cholongitas E, Burra P, Burroughs A. Veno occlusive disease: update on clinical management. World journal of gastroenterology: WJG. 2007;13(29):3918 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kakar F, Akbarian Z, Leslie T, Mustafa ML, Watson J, van Egmond HP, et al. An outbreak of hepatic veno-occlusive disease in Western Afghanistan associated with exposure to wheat flour contaminated with pyrrolizidine alkaloids. Journal of toxicology. 2010;2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Tandon BN, Tandon H, Tandon R, Narndranathan M, Joshi Y. An epidemic of veno-occlusive disease of liver in central India. The Lancet. 1976;308(7980):271–2. [DOI] [PubMed] [Google Scholar]
  • 12.Chiu C, Buttke D, Welde G, Luce R, Debela A, Bitew A, et al. Evaluation of the Pyrrolizidine Alkaloid Induced Liver Disease (PAILD) Active Surveillance System in Tigray, Ethiopia. 2013.
  • 13.Debella A, Abebe D, Tekabe F, Mamo H, Abebe A, Tsegaye B, et al. Toxicity study and evaluation of biochemical markers towards the identification of the causative agent for an outbreak of liver disease in Tahtay Koraro Woreda, Tigray. Ethiopian medical journal. 2012;50:27–35. [PubMed] [Google Scholar]
  • 14.Mesfin G, Ali A, Seboxa T, Bane A, Tensae MW, Gebressilassie S, et al. An epidemiological study into the investigation of liver disease of unknown origin in a rural community of northern Ethiopia, 2005. Ethiopian medical journal. 2012:1–8. [PubMed] [Google Scholar]
  • 15.Abebe D, Debella A, Tekabe F, Mekonnen Y, Degefa A, Mekonnen A, et al. An outbreak of liver disease in Tahtay Koraro Woreda, Tigray region of Ethiopia: a case-control study for the identification of the etiologic agent. Ethiopian medical journal. 2012;50:17–25. [PubMed] [Google Scholar]
  • 16.Tahtay Koraro Woreda Health Office Report. 2016.
  • 17.Afewerki M IT, Ahmed B. Technical report on pyrrolizidine alkaloids induced hepatic veno-occulusive disease (hepatic-VOD) from north western zones of Tigray, Ethiopia Addis Ababa Ethiopian public health association, April 2013.

Decision Letter 0

Raffaele Serra

19 Aug 2019

PONE-D-19-19407

Health impact of hepatic-venous occlusive disease in Tahtay Koraro district - Tigray region, Ethiopia, 2017

PLOS ONE

Dear Mrs Weldearegay,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The manuscript is potentially interesting provided the authors are willing to address reviewers' concerns.

We would appreciate receiving your revised manuscript by Oct 03 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Raffaele Serra, M.D., Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study. We note taht you mention that you "obtained written informed consent from the study participants". However, we note that some participants had died by the time your study was conducted. Please therefore ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

3. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), particularly in the Introduction, which needs to be addressed:

http://njmonline.nl/getpdf.php?id=933

https://doi.org/10.1016/S0973-6883(11)60128-X

https://doi.org/10.1016/0268-960X(93)90023-W

http://dx.doi.org/10.1155/2010/313280

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed.

4. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), particularly in the Introduction, which needs to be addressed:

http://njmonline.nl/getpdf.php?id=933

https://doi.org/10.1016/S0973-6883(11)60128-X

https://doi.org/10.1016/0268-960X(93)90023-W

http://dx.doi.org/10.1155/2010/313280

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed."""

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

6. Please ensure that you refer to Figures 1-4 in your text as, if accepted, production will need this reference to link the reader to the figure.

7. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 1 in your text; if accepted, production will need this reference to link the reader to the Table.

Additional Editor Comments:

The manuscript needs extensive revision according to reviewers' commnents.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The study titled 'Health impact of hepatic-venous occlusive disease in Tahtay Koraro district- Tigray region, Ethiopia, 2017 is a unique study that reports on the epidemiology of the disease in a small town in Ethiopia.Hepatic venous occlusive disease seems to be uniquely affecting this small village and the risk factors are not known. There is very scant information on the impact as well as epidemiology of the disease and hence the study is significant. However, the manuscripts needs some editing before it can be published.

1. the title could be modified to "Health impact of hepatic-venous occlusive disease in a small town in Ethiopia- case study from Tahtay Koraro district in Tigray region, 2017

2. the results in the abstract should describe the trend over time of VoD fatality given in figure 3. They should describe the change points in 2008/09 and 2009/10 and why these inflection years.

3. in the abstract, line 29, after however, they should add 'the problem...

4. on page 3, line 53, instead of saying 'according to ...., it is sounds better to say, 'It has been reported that the incidence ...

5. on page 4, line 69, they should add a couple of sentences that describe what the current gaps are what the study adds to the current literature. it looks like that there are only two studies (ref 12 and 14) that have been made on this disease but none of them are published. But, searching the internet with "hepatic-venous occlusive disease in Tahtay Koraro district- Tigray region" came up with may more studies that should be included in this review. For example, I listed 7 below (and there may be more)

0. Cindy Chiu,1 Colleen Martin,1 Daniel Woldemichael,2 Girmay W Selasie,2 Israel Tareke,3 Richard Luce,4 Gidey G Libanos,5 Danielle Hunt,1 Tesfaye Bayleyegn,1 Adamu Addissie,6 Danielle Buttke,1 Amsalu Bitew,7 Sara Vagi,1 Matthew Murphy,1 Teshale Seboxa,6 Daddi Jima,8 and Asfaw Debella8. SURVEILLANCE OF A CHRONIC LIVER DISEASE OF UNIDENTIFIED CAUSE IN A RURAL SETTING OF ETHIOPIA: A CASE STUDY. Ethiop Med J. 2016 Jan; 54(1): 27–32.

1. Bane A, Seboxa T, Mesfin G, Ali A, Tsegaye Y, M WT, et al. An outbreak of veno-occlusive liver disease in northern Ethiopia, clinical findings. Ethiopian medical journal. 2012 Apr;50(Suppl 2):9–16. PubMed PMID: 22946291. Epub 2012/09/06. eng. [PubMed] [Google Scholar]

2. Mesfin G, Ali A, Seboxa T, Bane A, Tensae MW, Gebressilassie S, et al. An epidemiological study into the investigation of liver disease of unknown origin in a rural community of northern Ethiopia, 2005. Ethiopian medical journal. 2012 Apr;50(Suppl 2):1–8. PubMed PMID: 22946290. [PubMed] [Google Scholar]

3. Schneider J, Tsegaye Y, M WT, S GS, Haile T, Bane A, et al. Veno-occlusive liver disease: a case report. Ethiopian medical journal. 2012 Apr;50(Suppl 2):47–51. PubMed PMID: 22946295. [PubMed] [Google Scholar]

4. Debella A, Abebe D, Tekabe F, Mamo H, Abebe A, Tsegaye B, et al. Toxicity study and evaluation of biochemical markers towards the identification of the causative agent for an outbreak of liver disease in Tahtay Koraro Woreda, Tigray. Ethiopian medical journal. 2012 Apr;50(Suppl 2):27–35. PubMed PMID: 22946293. [PubMed] [Google Scholar]

5. Abebe D, Debella A, Tekabe F, Mekonnen Y, Degefa A, Mekonnen A, et al. An outbreak of liver disease in Tahtay Koraro Woreda, Tigray region of Ethiopia: a case-control study for the identification of the etiologic agent. Ethiopian medical journal. 2012 Apr;50(Suppl 2):17–25. PubMed PMID: 22946292. [PubMed] [Google Scholar]

6. Debella A, Abebe D, Tekabe F, Degefa A, Desta A, Tefera A, et al. Physico-chemical investigation of consumables and environmental samples to determine the causative agent of liver disease outbreak in Tahitay Koraro Woreda, Tigray. Ethiopian medical journal. 2012 Apr;50(Suppl 2):37–45. PubMed PMID: 22946294. [PubMed] [Google Scholar]

6. On page 4, lines 72- please remove this line.

7. On page 4, line 76, please add population size.

8. the results section needs some editing with each table and figure described fully. Start as follows:

Table 1 shows ....

9. There are many typographical errors that need to be edited. The corresponding author's e-mail is misspelled, on page 5, line 97, Excel is misspelled.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mulugeta Gebregziabher, PhD

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2019 Nov 5;14(11):e0224659. doi: 10.1371/journal.pone.0224659.r002

Author response to Decision Letter 0


3 Oct 2019

Revisions made on the manuscript to be submitted to Plos one

Health impact of hepatic-venous-occlusive disease in small town in Ethiopia – case study from Tahtay Koraro district in Tigray region, 2017

Version: 1 Date: 26 September, 2019

Dear Editor-in-Chief:

Amendments made for the HVOD manuscript

Response to journal requirements’ comments

1. We have addressed the Plos one’s style requirement

2. Ethical review board had waived the requirement for informed consent.

3. The minor occurrence of overlapping text with previously published journals was rewritten and edited.

4. The data set is uploaded as supporting information file

5. We have referred the figures in our text

6. We have referred the table in our text

Response to reviewers’ comments

1. The Title was modified to Health impact of hepatic-venous-occlusive disease in small town in Ethiopia – case study from Tahtay Koraro district in Tigray region, 2017 as commented.

2. The result of abstract has included trend over time of VOD fatality.

3. In line 29 we have added the problem after however

4. Page 3 line 53 was modified to - in different literatures it has been reported that the incidence of VOD….

5. The comment given on page 4, line 69; We have added additional literatures concerned on hepatic-venous-occlusive disease in Tahtay koraro district

6. On page 4 line 72 we have removed the sentence according to the given comment

7. On page 4, line 76 we have included the population size of Tahtay Koraro district in 2017

8. In the result section we have edited each tables and figures by describing fully

9. The typographical errors were edited

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 1

Raffaele Serra

21 Oct 2019

Health impact of hepatic-venous-occlusive disease in small town in Ethiopia – case study from Tahtay Koraro district in Tigray region, 2017

PONE-D-19-19407R1

Dear Dr. Weldearegay,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Prof. Raffaele Serra, M.D., Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

amended manuscript is acceptable

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have responded to my comments. However, the manuscript still needs some editing. The organization of the results section as well as the flow of the paragraphs could be improved with some editorial help.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Raffaele Serra

24 Oct 2019

PONE-D-19-19407R1

Health impact of hepatic-venous-occlusive disease in a small town in Ethiopia – case study from Tahtay Koraro district in Tigray region, 2017    

Dear Dr. Weldearegay:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Raffaele Serra

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Data available.

    (SAV)

    Attachment

    Submitted filename: Response to reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES